Gastrodiae rhizoma oligosaccharide compound, and preparation method therefor and use thereof
By extracting and purifying oligosaccharide compounds from Gastrodia elata, the problem of difficulty in effectively improving sleep disorders in the prior art is solved, and the significant sleep-promoting effect with low side effects is achieved, which is suitable for the treatment and prevention of improving sleep disorders.
Patent Information
- Application Number
- PCT/CN2024/094488
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-21
- Publication Date
- 2024-11-28
AI Technical Summary
The prior art is difficult to effectively improve sleep disorders, especially in the trend of being more common and younger among the elderly, and traditional therapies have high side effects.
By extracting and purifying the oligosaccharide compounds in Gastrodia elata, Gastrodia elata oligosaccharide compounds with specific structures are prepared, and a pharmaceutical composition with a sleep-promoting effect is prepared by water extraction, alcohol precipitation, protein removal and purification steps.
The Gastrodia elata oligosaccharide compound significantly improves sleep disorders, has low side effects and high safety, can effectively promote sleep, and is suitable for treating and preventing sleep problems caused by diseases.
Smart Images

Figure CN2024094488_28112024_PF_FP_ABST
Abstract
Description
Gastrodia elata oligosaccharide compounds and preparation methods and applications thereof
[0001] Related applications
[0002] This application claims priority to Chinese patent application No. 202310576925X, filed on May 22, 2023, entitled “Gastrodia Oligosaccharide Compounds, Preparation Methods and Applications Thereof,” the entire text of which is hereby incorporated by reference. Technical Field
[0003] The present invention relates to the field of pharmaceutical technology, and in particular to a Gastrodia elata oligosaccharide compound, a preparation method and application thereof, and more particularly to a Gastrodia elata oligosaccharide compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, a preparation method thereof, a pharmaceutical composition, and application of a Gastrodia elata oligosaccharide compound having formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof in the preparation of a drug for treating and / or preventing sleep disorders caused by diseases. Background Art
[0004] Sleep disorders (somnipathies) refer to various functional impairments in the sleep-wake process, with decreased sleep quality being a primary manifestation. Studies have shown that nearly 300 million Chinese people suffer from sleep problems. Generally speaking, sleep disorders are more common among the elderly. For example, nearly 65% of people aged 65 and over experience various sleep issues. However, in recent years, sleep disorders have become younger, possibly related to the stress of modern life, such as anxiety, depression, unhealthy eating habits, lack of exercise, obesity, and other metabolic disorders. These factors often lead to shallow, fragmented sleep and even insomnia.
[0005] Traditional Chinese medicine has the advantages of multiple targets and few side effects. It is of great significance to study the components in traditional Chinese medicine that can improve sleep disorders.
[0006] Summary of the Invention
[0007] Based on this, according to various embodiments of the present application, there is provided a Gastrodia elata oligosaccharide compound having a structure shown in formula (I) that can improve sleep disorders, and a preparation method and application thereof, the technical solution is:
[0008] A Gastrodia elata oligosaccharide compound having a structure represented by formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof:
[0009] in:
[0010] n is any integer from 1 to 8;
[0011] X is H, a monosaccharide, or an oligosaccharide composed of m monosaccharides, where m is an integer from 2 to 20;
[0012] Y is H, a monosaccharide, or an oligosaccharide composed of k monosaccharides, where k is an integer from 2 to 10;
[0013] and the sum of the number of monosaccharides in X and Y is at least 2.
[0014] The second aspect of the present invention provides a method for preparing the above-mentioned Gastrodia oligosaccharide compound having formula (I) or its pharmaceutically acceptable salt or stereoisomer, and the technical scheme thereof is as follows:
[0015] A method for preparing the above-mentioned Gastrodia oligosaccharide compound of formula (I) or its pharmaceutically acceptable salt or stereoisomer thereof comprises the following steps:
[0016] Using water as an extraction solvent, extracting Gastrodia elata medicinal materials at 60°C to 100°C, and collecting the extract;
[0017] precipitating the extract with alcohol to prepare crude sugar;
[0018] The raw sugar is purified.
[0019] The third aspect of the present invention provides a pharmaceutical composition, the technical solution of which is as follows:
[0020] A pharmaceutical composition comprises the above-mentioned Gastrodia elata oligosaccharide compound of formula (I) or its pharmaceutically acceptable salt or stereoisomer.
[0021] The fourth aspect of the present invention provides the use of the above-mentioned Gastrodia elata oligosaccharide compound having formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof in the preparation of a drug for treating and / or preventing sleep disorders caused by diseases.
[0022] The details of one or more embodiments of the present application are set forth in the description below, and other features, objects, and advantages of the application will become apparent from the description and from the claims thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the conventional technology, the following briefly introduces the drawings required for use in the embodiments or the conventional technology descriptions. Obviously, the drawings described below are merely embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on the disclosed drawings without any creative work.
[0024] Figure 1 is the HPGPC spectrum of G305, G306 and G307;
[0025] Figure 2 is a schematic diagram of the drug administration mode;
[0026] Figure 3 is a time comparison diagram of the solvent control group and the G305 experimental group under different states of dark1, dark2, light1 and light;
[0027] Figure 4 is a time comparison diagram of the solvent control group and the G306 experimental group under different states of dark1, dark2, light1 and light;
[0028] FIG5 is a time comparison diagram of the solvent control group and the G305 experimental group at different states per hour;
[0029] Figure 6 is a comparison of delta waves between the solvent control group and the G305 experimental group every 2 hours;
[0030] FIG7 is a comparison of delta waves between the solvent control group and the G306 experimental group every 2 hours;
[0031] Figure 8 is a comparison of different activity states of the solvent control group and the G305 experimental group in the non-sleep phase under dark1, dark2, light1 and light. DETAILED DESCRIPTION
[0032] The following will be combined with the drawings in the embodiments of this application to clearly and completely describe the technical solutions in the embodiments of this application. Obviously, the embodiments described are only part of the embodiments of this application, not all of the embodiments. Based on the embodiments in this application, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of this application.
[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing specific embodiments only and are not intended to limit this application.
[0034] the term
[0035] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0036] In this application, the selection range involving "and / or", "or / and", and "and / or" includes any one of two or more related listed items, and also includes any and all combinations of the related listed items, and the said any and all combinations include any two related listed items, any more related listed items, or a combination of all related listed items. It should be noted that when at least three items are connected by at least two conjunctions selected from "and / or", "or / and", and "and / or", it should be understood that the technical solution undoubtedly includes technical solutions that are all connected by "logical and", and undoubtedly includes technical solutions that are all connected by "logical or". For example, "A and / or B" includes three parallel solutions of A, B and A+B. For example, the technical solution of "A, and / or, B, and / or, C, and / or, D" includes any one of A, B, C, and D (that is, the technical solution of all being connected by "logical OR"), and also includes any and all combinations of A, B, C, and D, that is, the combination of any two or any three of A, B, C, and D, and also includes the four-item combination of A, B, C, and D (that is, the technical solution of all being connected by "logical AND").
[0037] In this application, the terms "optionally," "optional," and "optional" refer to options that are optional and may or may not be present, i.e., to the selection of either option from the two parallel options of "with" or "without." If multiple "options" appear in a technical solution, unless otherwise specified and there are no contradictions or constraints, each "option" is independent.
[0038] In this application, the terms "first," "second," "third," "fourth," etc., in the "first aspect," "second aspect," "third aspect," "fourth aspect," etc., are used for descriptive purposes only and should not be understood as indicating or implying relative importance or quantity, nor as implicitly indicating the importance or quantity of the indicated technical features. Furthermore, "first," "second," "third," "fourth," etc., are only used for non-exhaustive enumeration and description purposes, and should be understood not to constitute a closed-ended limitation on quantity.
[0039] In this application, when referring to a numerical interval (i.e., a numerical range), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval and includes the two numerical endpoints of the numerical range (i.e., the minimum and maximum values), as well as each numerical value between the two numerical endpoints. Unless otherwise specified, when a numerical interval refers only to integers within the numerical interval, it includes the two endpoint integers of the numerical range, as well as each integer between the two endpoints. In this application, it is equivalent to directly listing each integer, such as t is an integer selected from 1 to 10, indicating that t is any integer selected from the group of integers consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be merged. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.
[0040] Unless otherwise specified, the temperature parameters in this application allow for both constant temperature treatment and temperature fluctuations within a certain temperature range. It should be understood that the constant temperature treatment allows for temperature fluctuations within the accuracy range of instrument control. Fluctuations within ranges such as ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are permitted.
[0041] In this application, when referring to percentage content, unless otherwise specified, for solid-liquid mixing and solid-solid mixing, it refers to mass percentage, and for liquid-liquid mixing, it refers to volume percentage.
[0042] In this application, references to percentage concentrations, unless otherwise specified, refer to final concentrations, which are the percentage of an added component in the system after the addition of that component.
[0043] In this application, % (w / w) and wt% both refer to weight percentage, % (v / v) refers to volume percentage, and % (w / v) refers to mass volume percentage.
[0044] Gastrodia elata is the dried tuber of Gastrodia elata (Gastrodia elata Bl.), an orchidaceous plant. The 2020 edition of the Pharmacopoeia of the People's Republic of China records that it has the effects of stopping wind and relieving spasms, calming liver yang, and dispelling wind and unblocking meridians. It is a Chinese medicine with the same origin as medicine and food, mainly containing chemical components such as phenol and its glycosides, organic acids, and polysaccharides. Current studies have found that Gastrodia elata has anticonvulsant, sedative, hypnotic, antidepressant effects, but what components in Gastrodia elata are related to improving sleep disorders is a problem that has not yet been broken through. The present invention provides a Gastrodia elata oligosaccharide compound with a structure shown in formula (I) by studying Gastrodia elata components. It has an obvious sleep-promoting effect, can be used to improve sleep disorders, and is rich in sources, has low side effects, and is safe.
[0045] One embodiment of the present invention provides a Gastrodia elata oligosaccharide compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof:
[0046] in:
[0047] n is any integer from 1 to 8;
[0048] X is H, a monosaccharide, or an oligosaccharide composed of m monosaccharides, where m is an integer from 2 to 20;
[0049] Y is H, a monosaccharide, or an oligosaccharide composed of k monosaccharides, where k is an integer from 2 to 10;
[0050] and the sum of the number of monosaccharides in X and Y is at least 2.
[0051] It is understood that n is 1, 2, 3, 4, 5, 6, 7 or 8.
[0052] m is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. Optionally, m is 2-8.
[0053] k is 2, 3, 4, 5, 6, 7, 8, 9 or 10. Optionally, m is 2-8.
[0054] Optionally, the Gastrodia elata oligosaccharide compound has a structure shown in any one of formulas (I-1) to (I-3):
[0055] In one example, the Gastrodia elata oligosaccharide compound has a structure shown in formula (I-1);
[0056] Wherein, X is H and Y is an oligosaccharide composed of k monosaccharides.
[0057] In one example, the Gastrodia elata oligosaccharide compound has a structure shown in formula (I-1);
[0058] Wherein, Y is H, and X is an oligosaccharide composed of m monosaccharides.
[0059] In one example, the Gastrodia elata oligosaccharide compound has a structure shown in formula (I-1);
[0060] Wherein, X is a monosaccharide, and Y is a monosaccharide or an oligosaccharide composed of k monosaccharides.
[0061] In one example, the Gastrodia elata oligosaccharide compound has a structure shown in formula (I-1);
[0062] Wherein, Y is a monosaccharide, and X is a monosaccharide or an oligosaccharide composed of m monosaccharides.
[0063] In one example, the Gastrodia elata oligosaccharide compound has a structure shown in formula (I-1);
[0064] Here, X is an oligosaccharide composed of m monosaccharides, Y is an oligosaccharide composed of k monosaccharides, and the sum of m and k is an integer between 4 and 20.
[0065] Optionally, the connection mode of the glycosidic bonds between the m monosaccharides in X includes one or more of 1,2-linkage, 1,3-linkage, 1,4-linkage, 1,6-linkage, 1,4,6-linkage and terminal linkage.
[0066] Optionally, the connection mode of the glycosidic bonds between the k monosaccharides in Y includes one or more of 1,2-linkage, 1,3-linkage, 1,4-linkage, 1,6-linkage, 1,4,6-linkage and end-group linkage.
[0067] Alternatively, the monosaccharide at the terminal group in X forms a glycosidic bond with the O connected to the benzene ring through the 1 position.
[0068] Alternatively, the monosaccharide at the terminal group in Y forms a glycosidic bond with the O connected to the benzene ring through the 1 position.
[0069] It can be understood that when X is a monosaccharide, the monosaccharide at the terminal group refers to the monosaccharide itself, and the monosaccharide forms a glycosidic bond with the O group connected to the benzene ring through the 1-position. Similarly, when Y is a monosaccharide, the monosaccharide at the terminal group refers to the monosaccharide itself, and the monosaccharide forms a glycosidic bond with the O group connected to the benzene ring through the 1-position.
[0070] Optionally, each occurrence of the monosaccharide in X and the monosaccharide in Y is independently one or more of glucose, mannose, galactose and galacturonic acid. Preferably, each occurrence of the monosaccharide in X and the monosaccharide in Y is glucose.
[0071] Optionally, the peak molecular weight of the Gastrodia elata oligosaccharide compound is 400Da to 1200Da. For example, the peak molecular weight of the Gastrodia elata oligosaccharide compound includes but is not limited to: 600Da, 650Da, 700Da, 750Da, 800Da, 850Da, 900Da, 950Da, 1000Da, 1050Da, 1100Da, 1150Da, 1200Da.
[0072] Optionally, the total sugar content of the Gastrodia elata oligosaccharide compound is 70% to 90%. For example, the total sugar content of the Gastrodia elata oligosaccharide compound includes but is not limited to: 70%, 71%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%.
[0073] The above embodiment provides a Gastrodia elata oligosaccharide compound having a structure shown in formula (I) by studying the components of Gastrodia elata, which has a significant sleep-promoting effect and can be used to improve sleep disorders. It is also rich in sources, has low side effects, and is safe.
[0074] The above-mentioned Gastrodia elata oligosaccharide compound of formula (I) or its pharmaceutically acceptable salt or stereoisomer can be obtained by direct extraction and purification from Gastrodia elata medicinal materials, or by hydrolysis or degradation of the sugar components in Gastrodia elata medicinal materials.
[0075] One embodiment of the present invention further provides a method for preparing the above-mentioned Gastrodia oligosaccharide compound having formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, which comprises the following steps:
[0076] A method for preparing the above-mentioned Gastrodia oligosaccharide compound of formula (I) or its pharmaceutically acceptable salt or stereoisomer thereof comprises the following steps:
[0077] Using water as an extraction solvent, extracting Gastrodia elata medicinal materials at 60° C. to 100° C., and collecting the extract;
[0078] precipitating the extract with alcohol to prepare crude sugar;
[0079] The raw sugar is purified.
[0080] It will be appreciated that the extraction temperature may be 60°C, 70°C, 80°C, 90°C or 100°C.
[0081] Optionally, the extraction is performed 1 to 3 times. After each extraction, the filtrates are combined to obtain an extract.
[0082] Furthermore, during each extraction, the mass of the water is independently 20 to 50 times the mass of the Gastrodia elata medicinal material. For example, the mass of the water is 20, 30, 40 or 50 times the mass of the Gastrodia elata medicinal material.
[0083] Furthermore, the extraction time of each extraction is independently 1 hour to 4 hours. For example, the extraction time is 1 hour, 2 hours, 3 hours or 4 hours.
[0084] In this embodiment, the extract is precipitated with ethanol, and the step of concentrating the extract is also included before the precipitation. Optionally, the ethanol can be provided by an ethanol-water solution. Furthermore, the concentration of the ethanol-water solution can be 90% to 98%. For example, it can be 90%, 95%, or 98%.
[0085] The alcohol precipitation can be performed once or multiple times, such as twice, three times or four times, with ethanol being used independently for each alcohol precipitation.
[0086] After alcohol precipitation, the solid precipitate was collected by filtration.
[0087] Optionally, the preparation of the raw sugar further comprises the step of removing protein from the solid sediment obtained after the extract is precipitated with alcohol.
[0088] Furthermore, the protein removal process comprises the following steps:
[0089] The solid sediment is dissolved using water as solvent, and a protein removal reagent is added.
[0090] Alternatively, the protein removal agent may be a trichloroacetic acid aqueous solution.
[0091] The concentration is 5%-15%. For example, the concentration of trichloroacetic acid aqueous solution is 5%. The deproteinizing reagent can also be Sevage reagent (chloroform: n-butanol = 4:1).
[0092] In this embodiment, the raw sugar is obtained by removing protein, collecting the solid and cold drying it.
[0093] Optionally, purifying the raw sugar comprises the following steps:
[0094] dissolving the raw sugar to obtain a raw sugar solution;
[0095] The crude sugar solution is first purified using an anion exchange column, eluted with water, and the first fraction with a sugar color reaction and a peak molecular weight below 20 kDa is collected;
[0096] performing a second purification on the first fraction using a gel chromatography column or a membrane separation method, and collecting a second fraction having a sugar color reaction and a peak molecular weight below 3 kDa;
[0097] The second fraction was dried.
[0098] Optionally, the solvent for the crude sugar is water. After dissolution, the supernatant is collected by centrifugation as the crude sugar solution.
[0099] Optionally, the anion exchange column is a DEAE-cellulose column.
[0100] In this embodiment, the crude sugar solution is added to a DEAE-cellulose column for first purification, eluted with water as the eluent, and the fractions are collected.
[0101] Optionally, the volume of water is greater than 2 column volumes.
[0102] Optionally, the flow rate is 5 mL / min to 15 mL / min, for example, 5 mL / min, 10 mL / min, or 15 mL / min.
[0103] The absorbance of each fraction at 490 nm (after color development using the sulfuric acid-phenol method) is measured using a septum tube, and the peak molecular weight of each fraction is measured (HPGPC detection). Fractions with a sugar color reaction and a peak molecular weight below 20 kDa are combined to obtain a first fraction. Optionally, the preparation of the first fraction further includes a concentration step after combining the fractions.
[0104] In this embodiment, the first fraction can be added to a gel chromatography column for secondary purification, eluted with water as the eluent, and the fractions collected. Alternatively, the first fraction can be added to a membrane separator, separated using a 3 kDa to 5 kDa membrane, and the fractions smaller than the 3 kDa to 5 kDa membrane can be collected.
[0105] The absorbance of each fraction at 490 nm (after color development using the sulfuric acid-phenol method) is measured using a septum tube, and the peak molecular weight of each fraction is measured (HPGPC detection). Fractions with sugar color development and a peak molecular weight below 3 kDa are combined to obtain a second fraction. Optionally, the preparation of the second fraction further includes a concentration step after combining the fractions.
[0106] After freeze-drying the second fraction, the Gastrodia elata oligosaccharide compound having the formula (I) is obtained.
[0107] One embodiment of the present invention further provides a pharmaceutical composition comprising the above-mentioned Gastrodia elata oligosaccharide compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.
[0108] The above-mentioned Gastrodia oligosaccharide compound of formula (I) or its pharmaceutically acceptable salt or stereoisomer can be used as an active ingredient, has a significant sleep-promoting effect, and can be used to improve sleep disorders.
[0109] Optionally, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier refers to a pharmaceutically acceptable carrier well known to those skilled in the art. Pharmaceutically acceptable carriers of the present invention include, but are not limited to, fillers, wetting agents, binders, disintegrants, lubricants, adhesives, glidants, taste-masking agents, surfactants, preservatives, and the like. Fillers include, but are not limited to, lactose, microcrystalline cellulose, starch, powdered sugar, dextrin, mannitol, and calcium sulfate. Wetting agents and binders include, but are not limited to, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, gelatin, sucrose, and polyvinyl pyrrolidone. Disintegrants include, but are not limited to, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose. Lubricants include, but are not limited to, magnesium stearate, micronized silica gel, talc, hydrogenated vegetable oil, polyethylene glycol, and magnesium lauryl sulfate. Binders include, but are not limited to, gum arabic, alginic acid, carboxymethylcellulose calcium, sodium carboxymethylcellulose, dextrates, dextrin, dextrose, ethylcellulose, gelatin, liquid glucose, guar gum, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylate, polyvinylpyrrolidone, pregelatinized starch, sodium alginate, sorbitol, starch, syrup, and tragacanth gum. Glidants include, but are not limited to, colloidal silicon dioxide, powdered cellulose, magnesium trisilicate, silicon dioxide, and talc. Taste-masking agents include, but are not limited to, aspartame, stevioside, fructose, glucose, syrup, honey, xylitol, mannitol, lactose, sorbitol, maltitol, and glycyrrhizin. Surfactants include, but are not limited to, Tween-80 and poloxamer. Preservatives include, but are not limited to, parabens, sodium benzoate, and potassium sorbate.
[0110] Alternatively, the dosage form of the pharmaceutical composition can be tablets, hard capsules, soft capsules, enteric-coated capsules, microcapsules, granules, syrups, injections, granules, emulsions, suspensions, solutions and sustained-release preparations for oral or parenteral administration.
[0111] One embodiment of the present invention also provides the use of the above-mentioned Gastrodia oligosaccharide compound having formula (I) or its pharmaceutically acceptable salt or stereoisomer in the preparation of a drug for treating and / or preventing sleep disorders caused by diseases.
[0112] Optionally, the disease is cancer, hypertension, depression, anxiety, autism, bipolar disorder or post-traumatic stress disorder.
[0113] The following is further described in conjunction with specific examples and comparative examples. Unless otherwise specified, the raw materials involved in the following specific examples and comparative examples can be sourced from commercial sources. The instruments used can be sourced from commercial sources unless otherwise specified. The processes involved can be selected conventionally by those skilled in the art unless otherwise specified.
[0114] Example 1
[0115] This embodiment provides a method for preparing a Gastrodia elata oligosaccharide compound G305, comprising the following steps:
[0116] Gastrodia elata (approximately 4 kg) was ground and passed through a No. 1 sieve. Extraction was performed at 70°C for 3 hours with 30-fold water. This extraction was repeated three times. The filtrates were combined to obtain an extract. The extract was concentrated, and 95% ethanol was slowly added to a concentration of 60%. The extract was allowed to stand at 4°C overnight. After filtration, the supernatant was concentrated under reduced pressure, and anhydrous ethanol was slowly added to a concentration of 95% ethanol. The extract was allowed to stand at 4°C overnight. The solid precipitate was collected after filtration. The resulting solid precipitate was dissolved in water and deproteinized with trichloroacetic acid. The solid was collected and freeze-dried to obtain crude sugar. The crude sugar was dissolved in distilled water, centrifuged, and the supernatant was applied to a DEAE-cellulose column for primary purification. Elution was performed with distilled water, with an elution volume greater than 2 column volumes, at a flow rate of 10 mL / min. Fractions were collected and measured for absorbance at 490 nm (after development with sulfuric acid-phenol). The peak molecular weight of each fraction was determined (HPGPC). Fractions with sugar color development and a peak molecular weight below 20 kDa were combined and concentrated to obtain the first fraction. The first fraction was added to a gel chromatography column for secondary purification, eluted with pure water as the eluent, and the fractions were collected. The absorbance value at 490 nm (after sulfuric acid-phenol color development) was detected, and the peak molecular weight of each fraction was detected (HPGPC detection). The fractions with sugar color reaction and peak molecular weight below 3 kDa were combined, concentrated to obtain the second fraction, and freeze-dried to obtain G305.
[0117] Example 2
[0118] This embodiment provides a method for preparing a Gastrodia elata oligosaccharide compound G306, comprising the following steps:
[0119] Gastrodia elata (Gastrodia elata) was ground and passed through a No. 2 sieve, leaving approximately 5 kg of the material. Extraction was performed at 70°C for 2 hours with 40 times the volume of water. This extraction was repeated three times. The filtrates were combined to obtain an extract. The extract was concentrated, and 95% ethanol was slowly added to a concentration of 50%. The mixture was allowed to stand at 4°C overnight. After filtration, the supernatant was concentrated under reduced pressure, and anhydrous ethanol was slowly added to a concentration of 90%. The mixture was allowed to stand at 4°C overnight. The solid precipitate was collected after filtration. The resulting solid precipitate was dissolved in water and deproteinized with Sevage reagent. The solid was collected and freeze-dried to obtain crude sugar. The crude sugar was dissolved in distilled water, centrifuged, and the supernatant was applied to a DEAE-cellulose column for primary purification. Elution was performed with distilled water, with an elution volume greater than 2 column volumes, at a flow rate of 10 mL / min. Fractions were collected and measured for absorbance at 490 nm (after development with sulfuric acid-phenol). The peak molecular weight of each fraction was determined (HPGPC). Fractions showing a sugar color reaction and a peak molecular weight below 20 kDa were combined and concentrated to obtain the first fraction. The first fraction was added to a membrane separator (3 kDa membrane) for secondary purification, the fractions were collected, the absorbance at 490 nm (after color development by sulfuric acid-phenol method) was detected, the fractions with sugar color development reaction were combined, concentrated to obtain the second fraction, and freeze-dried to obtain G306.
[0120] Example 3
[0121] This embodiment provides a method for preparing a Gastrodia elata oligosaccharide compound G307, comprising the following steps:
[0122] Gastrodia elata (approximately 3 kg) was ground and passed through a No. 1 sieve. Extraction was performed at 90°C for 3 hours with 30 times the amount of water. The extraction was repeated three times. The filtrates were combined to obtain an extract. The extract was concentrated, and 95% ethanol was slowly added to a concentration of 50%. The extract was allowed to stand at 4°C overnight. After filtration, the supernatant was concentrated under reduced pressure, and anhydrous ethanol was slowly added to a concentration of 90%. The extract was allowed to stand at 4°C overnight. The solid precipitate was collected after filtration. The solid precipitate was dissolved in water and deproteinized with trichloroacetic acid solution. The solid was collected and freeze-dried to obtain crude sugar. The crude sugar was dissolved in distilled water and centrifuged. The supernatant was added to a DEAE-cellulose column for the first purification, first eluted with distilled water and then with a NaCl solution. The elution volume was greater than 2 times the column volume and the flow rate was 10 mL / min. The NaCl solution eluted fraction was collected and the absorbance at 490 nm (after sulfuric acid-phenol color development) was detected. The peak molecular weight of each fraction was detected (HPGPC detection). The fractions with sugar color reaction and peak molecular weight below 20 kDa were combined, concentrated, and dialyzed to remove NaCl to obtain the first fraction. The first fraction was added to a membrane separator (3 kDa membrane) for the second purification, and the fractions were collected and the absorbance at 490 nm (after sulfuric acid-phenol color development) was detected. The fractions with sugar color reaction were combined and concentrated to obtain the second fraction, which was freeze-dried to obtain G307.
[0123] Compound structure characterization
[0124] 1 Determination of molecular weight
[0125] 1.1 Principle of determination
[0126] The relative molecular weight (peak molecular weight) of the products obtained in each example was determined using high performance gel permeation chromatography (HPGPC). The basic principle is that when a homogeneous substance passes through gel permeation chromatography, symmetrical chromatographic peaks are formed. The molecular weight is related to the peak appearance time, with substances with larger molecular weight appearing first and substances with smaller molecular weight appearing later. The relative molecular weight is then calculated based on a calibration curve derived from a series of substances with known molecular weights.
[0127] 1.2 Chromatographic conditions
[0128] Using TSK GMPW XL Gel chromatography column separation was performed on an Agilent 1260 liquid phase system with ultrapure water as the mobile phase, a flow rate of 0.8 mL / min, an injection volume of 20 μL, a column temperature of 25°C, and an evaporative light scattering detector (ELSD).
[0129] 1.3 Experimental methods
[0130] Accurately weigh 2.0 mg of each product obtained in each example and Dextrans series standard product, prepare a 2.0 mg / mL solution with ultrapure water, filter with a 0.45 μm microporous filter membrane, and then inject and test. Record the retention time. See Figure 1. Figure 1 is the HPGPC spectrum of G305, G306, and G307. It can be seen that the molecular weight uniformity of G305, G306, and G307 is good. The logarithm value (Lg) of the molecular weight of the known standard polysaccharide is used as the ordinate and the retention time is used as the abscissa to draw a standard curve, and the corresponding linear regression equation is obtained. Substituting the retention times of G305, G306, and G307 into the linear regression equation, the peak molecular weight of G305 is calculated to be 735 Da, the peak molecular weight of G306 is 674 Da, and the peak molecular weight of G307 is 853 Da.
[0131] 2 Determination of total sugar content
[0132] The total sugar content of the products obtained in each example was determined by the phenol-sulfuric acid method, and the total sugar content of G305 was 86.99%, the total sugar content of G306 was 83.31%, and the total sugar content of G307 was 77.46%.
[0133] 3 Monosaccharide composition analysis
[0134] Weigh 2 mg of the product obtained in each example into a reaction flask, add 500 μL of 2 mol / L trifluoroacetic acid (TFA) solution, and hydrolyze and seal the reaction in a constant temperature oven at 110°C for 5 hours. After cooling to room temperature, add 0.5 mL of methanol and place in a vacuum drying oven at 60°C, repeat 3 times to completely remove the trifluoroacetic acid. Add 0.13 mL of water and 0.30 mL of 0.15 mol / L sodium hydroxide solution to the residue and dissolve it. Then add 0.5 mL of 0.1 mol / L PMP methanol solution, seal it, mix it ultrasonically, and react at 70°C for 30 minutes. After taking it out and cooling it to room temperature, add 0.3 mL of 0.15 mol / L hydrochloric acid solution to neutralize it, transfer it to a 5 mL volumetric flask, add water to the mark, mix it, filter it through a 0.45 μm filter membrane, and take the filtrate for liquid phase analysis.
[0135] The results showed that the monosaccharide compositions of G305 and G306 were both glucose, and the monosaccharide composition of G307 was glucose, mannose, galactose and galacturonic acid.
[0136] 4 Methylation analysis
[0137] The products obtained in each example were methylated using a modified Hakomori method. The completeness of the methylation was detected by infrared spectroscopy. The methylated products were fully hydrolyzed with 2 mol / L TFA, reduced with NaBD4, and acetylated with acetic anhydride to prepare partially methylated Aldrin acetate derivatives, which were then analyzed by GC-MS.
[0138] Combined with the standard map, the methylation results of G305 showed that the structure contained terminal linkage, 1,4-linkage, 1,6-linkage and 1,4,6-linkage.
[0139] The methylation results of G306 showed that the structure contained terminal linkage, 1,3 linkage, 1,4-linkage and 1,6-linkage.
[0140] The methylation results of G307 showed that the structure contained terminal linkage, 1,2-linkage, 1,3-linkage, 1,4-linkage, 1,6-linkage and 1,4,6-linkage.
[0141] Effect verification experiment
[0142] 1 Experimental Materials
[0143] 1.1 Drugs and Reagents
[0144] The products obtained in each example are light yellow powders, easily soluble in water; 0.9% physiological saline is provided by Heilongjiang Qitai Animal Health Products Co., Ltd.
[0145] 1.2 Experimental animals
[0146] C57 mice, 4 months old, male, weighing 30 g, were provided by Jiangsu Jicui Pharmaceutical Biotechnology Co., Ltd.
[0147] 1.3 Experimental instruments
[0148] 6-channel physiological signal recorder (Jiangsu Yige Biotechnology Co., Ltd.); mouse brain stereotaxic apparatus (Shenzhen Ruiwode Life Science Technology Co., Ltd.); plexiglass cage.
[0149] 2 Experimental methods
[0150] 2.1 Animal grouping and drug administration
[0151] Mice were acclimated to a 12-hour light-dark cycle for 7 days. General anesthesia was administered by inhalation of isoflurane, and the brain was fixed in a stereotaxic apparatus. The skin of the head was cut open to form a cross, fully exposing the skull. The periosteum was stripped off, and two screws were clamped with hemostats and inserted into the skull at the intersection 1 mm anterior to the coronal suture and 1 mm anterior to the lambdoid suture, 1 mm to the right of the midline of the skull. The screws were placed in contact with the dura mater but did not penetrate the dura mater. These served as cortical electrodes for recording EEG. After surgery, the rats were placed in a custom-made plexiglass cage and waited for recovery from anesthesia. They were then housed individually in a shielded room (with 12-hour automatic light-dark cycle, constant temperature (22 ± 2°C), and relative humidity 45% to 50%) for 1 week of recovery before testing.
[0152] For mice with embedded recording electrodes, refer to the dosing pattern of Figure 2. At 21:00 on day 1, saline was injected intraperitoneally, and the electroencephalogram (EEG) signals of the mice were recorded, serving as the solvent control group. The recording time was from 21:00 on day 1 to 21:00 on day 2. Among them, 21:00 on day 1 to 3:00 in the morning of day 2 was recorded as dark1; 3:00 in the morning of day 2 to 9:00 in the morning of day 2 was recorded as dark2; 9:00 in the morning of day 2 to 15:00 in the afternoon of day 2 was recorded as light1; 15:00 in the afternoon of day 2 to 21:00 in the evening of day 2 was recorded as light2. At 21:00 on day 2, the same volume of the product obtained in each embodiment was again administered to the same mouse by intraperitoneal injection, serving as the experimental group. The recording time was from 21:00 on day 2 to 21:00 on day 3. Among them, the period from 21:00 on day 2 to 3:00 on day 3 was recorded as dark1; the period from 3:00 on day 3 to 9:00 on day 3 was recorded as dark2; the period from 9:00 on day 3 to 15:00 on day 3 was recorded as light1; and the period from 15:00 on day 3 to 21:00 on day 3 was recorded as light2. The EEG change characteristics between the two groups were analyzed and compared.
[0153] 3 Statistical processing
[0154] Data were analyzed using paired t-test.
[0155] 4 Experimental results
[0156] 4.1 Sleep-promoting effects of the products obtained in each example
[0157] Figure 3 shows a comparison of the time spent in different states under dark 1, dark 2, light 1, and light 2 in the solvent control group and the G305 experimental group. Figure 3A shows the comparison of total wakefulness time before and after drug administration, Figure 3B shows the comparison of NREM (non-rapid eye movement) sleep time before and after drug administration, Figure 3C shows the comparison of REM (rapid eye movement) sleep time before and after drug administration, and Figure 3D shows the comparison of total sleep time before and after drug administration. Figure 4 shows a comparison of the time spent in different states under dark 1, dark 2, light 1, and light 2 in the solvent control group and the G306 experimental group. Figure 4A shows the comparison of total wakefulness time before and after drug administration, Figure 4B shows the comparison of NREM sleep time before and after drug administration, Figure 4C shows the comparison of REM sleep time before and after drug administration, and Figure 4D shows the comparison of total sleep time.
[0158] It can be seen that G305 and G306 have a significant promoting effect on sleep, especially NREM sleep.
[0159] Taking G305 as an example, Figure 5 is a time comparison chart of the solvent control group and the G305 experimental group in different states per hour, among which Figure 5A is a comparison of the awake time per hour before and after administration, Figure 5B is a comparison of the NREM sleep time per hour, and Figure 5C is a comparison of the REM sleep time per hour. It was found that G305 took effect quickly, with a trend of increasing sleep in the first hour, and a significant difference in sleep time in the second hour. The increased sleep was mainly NREM sleep. In the natural sleep phase after administration (12th to 24th hour), the drug-administered group did not show compensatory sleep reduction, which means that G305 changes the set point of sleep homeostasis. This also means that the possibility of rebound early awakening in future clinical medication is relatively low, and the time that G305 affects sleep is about 7 to 8 hours, and the duration of drug effect is consistent with the average daily sleep duration of humans.
[0160] 4.2 Sleep pressure regulating effects of the products obtained in each example
[0161] Figure 6 shows a comparison of delta waves between the solvent control group and the G305 experimental group every 2 hours. Figure 7 shows a comparison of delta waves between the solvent control group and the G306 experimental group every 2 hours. For most animals, delta waves fluctuate regularly throughout a sleep cycle. They peak at the onset of sleep, then gradually decrease as sleep progresses, reaching a low point during wakefulness. They then increase cumulatively as wakefulness prolongs, until reaching a peak at the beginning of the next sleep phase. In this experiment, due to the hypnotic effect of G305, sleep pressure tended to decrease 8 to 12 hours after administration; however, in the next sleep phase (7 (14 hours) in Figure 6), sleep pressure in the drug-treated group increased, and sleep tended to deepen. G306, on the other hand, showed a decrease in sleep pressure during the first sleep phase.
[0162] 4.3 Effects of the products obtained in each example on regulating sleep-related behaviors such as diet and activity
[0163] Taking G305 as an example, an activity-eating system was used to record changes in animal activity before and after G305 administration. These activities all occurred during the non-sleep phase, thus supporting changes in sleep, as shown in Figure 8. Figure 8A shows the comparison of horizontal activity distance before and after administration, Figure 8B shows the comparison of the number of standing times, Figure 8C shows the comparison of food intake, and Figure 8D shows the comparison of water intake. The results showed that the G305-treated group showed a significant decrease in horizontal and vertical movement, food intake, and water intake 6 hours after administration, which is consistent with the sleep-promoting effect of G305.
[0164] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0165] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the patent application. It should be noted that a person of ordinary skill in the art may make various modifications and improvements without departing from the spirit of the present application, and these modifications and improvements fall within the scope of protection of the present application. Therefore, the scope of protection of the present patent application shall be determined by the appended claims.
Claims
1. A Gastrodia elata oligosaccharide compound having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof: in: n is any integer from 1 to 8; X is H, a monosaccharide or an oligosaccharide composed of m monosaccharides, where m is any integer from 2 to 20; Y is H, a monosaccharide or an oligosaccharide composed of k monosaccharides, where k is any integer from 2 to 10; And the sum of the number of monosaccharides in X and Y is at least 2.
2. The Gastrodia elata oligosaccharide compound or its pharmaceutically acceptable salt or its stereoisomer according to claim 1, characterized in that: The Gastrodia elata oligosaccharide compound has a structure shown in any one of formulas (I-1) to (I-3):
3. The Gastrodia elata oligosaccharide compound or its pharmaceutically acceptable salt or its stereoisomer according to claim 2, characterized in that: The Gastrodia elata oligosaccharide compound has a structure shown in formula (I-1); wherein X is H, and Y is an oligosaccharide composed of k monosaccharides; or Y is H, and X is an oligosaccharide composed of m monosaccharides; or X is a monosaccharide, and Y is a monosaccharide or an oligosaccharide composed of k monosaccharides; or Y is a monosaccharide, and X is a monosaccharide or an oligosaccharide composed of m monosaccharides; or X is an oligosaccharide composed of m monosaccharides, Y is an oligosaccharide composed of k monosaccharides, and the sum of m and k is any integer between 4 and 20.
4. The Gastrodia elata oligosaccharide compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 3, characterized in that: The connection modes of the glycosidic bonds between the m monosaccharides in X include one or more of 1,2-linkage, 1,3-linkage, 1,4-linkage, 1,6-linkage, 1,4,6-linkage and terminal-linkage.
5. The Gastrodia elata oligosaccharide compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 3, characterized in that: The connection modes of the glycosidic bonds between the k monosaccharides in Y include one or more of 1,2-linkage, 1,3-linkage, 1,4-linkage, 1,6-linkage, 1,4,6-linkage and terminal linkage.
6. The Gastrodia elata oligosaccharide compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 3, characterized in that: The monosaccharide at the terminal group in X forms a glycosidic bond with the O connected to the benzene ring through the 1 position.
7. The Gastrodia oligosaccharide compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 3, characterized in that: The monosaccharide at the terminal group in Y forms a glycosidic bond with the O connected to the benzene ring through the 1 position.
8. The Gastrodia oligosaccharide compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 3, characterized in that: Each time the monosaccharide in X and the monosaccharide in Y appear, they are independently one or more of glucose, mannose, galactose and galacturonic acid.
9. The Gastrodia elata oligosaccharide compound or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 8, characterized in that: The peak molecular weight of the Gastrodia elata oligosaccharide compound is 400Da to 1200Da.
10. The Gastrodia elata oligosaccharide compound or its pharmaceutically acceptable salt or stereoisomer thereof according to claims 1 to 8, characterized in that: The total sugar content of the gastrodia elata oligosaccharide compound is 70% to 90%.
11. A method for preparing the Gastrodia elata oligosaccharide compound of formula (I) or its pharmaceutically acceptable salt or stereoisomer thereof according to any one of claims 1 to 10, characterized in that: The following steps are involved: Using water as an extraction solvent, extracting the Gastrodia elata medicinal material at 60°C to 100°C, and collecting the extract; precipitating the extract with alcohol to prepare crude sugar; The raw sugar is purified.
12. The preparation method according to claim 11, characterized in that: Purifying the raw sugar comprises the following steps: dissolving the raw sugar to obtain a raw sugar solution; The crude sugar solution is first purified by using an anion exchange column, eluted with water as an eluent, and a first fraction having a sugar color reaction and a peak molecular weight below 20 kDa is collected; Performing a second purification on the first fraction using a gel chromatography column or a membrane separation method, and collecting a second fraction having a sugar color reaction and a peak molecular weight below 3 kDa; The second fraction was dried.
13. A pharmaceutical composition, characterized in that It includes the Gastrodia elata oligosaccharide compound having formula (I) as described in any one of claims 1 to 10, or its pharmaceutically acceptable salt or stereoisomer.
14. Use of the Gastrodia elata oligosaccharide compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of claims 1 to 10 in the preparation of a medicament for treating and / or preventing sleep disorders or sleep disorders caused by diseases.
15. The use according to claim 14, characterized in that: The disease is cancer, hypertension, depression, anxiety, autism, bipolar disorder or post-traumatic stress disorder.
Citation Information
Patent Citations
Gastrodia elata BL. polysaccharide and degradation products thereof and preparation methods and applications of degradation products
CN102464725A
Gastrodia elata macromolecular linear straight-chain glucan and preparation method and application thereof
CN112574326A
Extraction method and application of gastrodia elata oligosaccharide GEP-2
CN114133461A
Gastrodia elata homogeneous polysaccharide as well as preparation method and application thereof
CN114805629A
Gastrodia elata polysaccharide with immunoregulatory activity
CN115558035A
